Toxicologist warns doctors on analgesics

A TGA decision to remove the two dextropropoxyphene-containing painkillers from the register was overturned by the Administrative Appeals Tribunal (AAT) earlier this year, despite a risk of cardiotoxicity in patients with renal impairment, drug interactions and overdose.

The TGA and manufacturer Aspen Pharmacare are awaiting an AAT decision on what conditions will be imposed on use of the drugs, with federal court action not ruled out by the regulator.